ClinicalTrials.gg
CompletedNCT01450813Updated May 12, 2017Results posted

The Effect of Neuromuscular Blockade on the Composite Variability Index (CVI) During Laryngoscopy

An interventional study of Saline 0.06 ml/kg and Rocuronium 0.2 mg/kg in Anesthesia and Neuromuscular Blockade, sponsored by Medtronic - MITG. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-05-12.

Sponsored by Medtronic - MITG (part of Medtronic) · Not applicable, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The Bispectral Index (BIS) monitor is used in many operating rooms to provide information to the anesthesiologist about a patient's level of consciousness. The Composite Variability Index (CVI) is a new index that may provide the anesthesiologist with more information about the condition of the patient. The CVI is a measure of the combined variability in BIS (bispectral index) and frontal electromyography (EMG) activity that may be useful in assessing the nociception/anti-nociception balance for patients under general anesthesia.The purpose of this study is to determine if a commonly used anesthetic drug (rocuronium) affects the CVI measurement differently with different doses. Rocuronium is a neuromuscular blocking agent (NMBA) routinely used during surgery. It is expected that the group given the highest dose of rocuronium will have diminished CVI values.

This study will randomize patients to one of four doses of rocuronium: no rocuronium, 0.2, 0.4, and 0.6 milligrams per kilo of body weight; the last dose is the standard amount for adults. It is expected that the group given the highest dose of rocuronium will have diminished CVI values. By including intermediate doses, information about the function of CVI in states of less than full muscle relaxation, or paralysis, will be obtained. This information is critically important for the development of the composite variability index, because during general anesthesia patients are usually maintained in a state of less than full paralysis. If the CVI response to stimulation in the intermediate groups is similar to the group receiving no rocuronium, the monitor may find wide clinical applicability. If the response is similar to the maximal rocuronium group, the index may only be reliable in states with no muscle relaxant, which will greatly limit clinical utility.

Read the detailed description

Consented subjects randomized to one of four doses of rocuronium will be transported to the operating room and be connected to routine monitors that included a BIS (Covidien), M-Entropy sensor (GE Healthcare) and TOF (train of four) monitor. Following preoxygenation, general anesthesia will be induced with propofol and remifentanil using traditional syringe pumps. The induction doses given and subsequent infusion rates will be determined by utilizing pharmacokinetic (Pk) models (Marsh model for propofol, Minto model for remifentanil). Unconsciousness will be confirmed by performing the usual clinical assessments and by obtaining a BIS value between 40 and 50. Once the subject is unconsciousness, they will be given the assigned dose of rocuronium, after which the study anesthesiologist will perform a laryngoscopy. The anesthesiologist performing the laryngoscopy will not know what dose of rocuronium the subject received. Neuromuscular blockade (NMB) will be monitored by a train-of-four twitch monitor (TOF Watch-SX) at the adductor pollicis muscle (2 HZ, 50mAmp) every 15 seconds.

At three minutes after the rocuronium administration, a standardized 20-second laryngoscopy will be applied. The CVI, entropy, and hemodynamic responses (heart rate, blood pressure measurement each minute) and train-of-four measurements will be monitored for three minutes before and after the laryngoscopy.

02

Conditions studied

  • Anesthesia
  • Neuromuscular Blockade
03

In context

Lead sponsor

Medtronic - MITG is the lead sponsor of 179 studies on the registry; 4 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 17 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • American Society of Anesthesia (ASA) physical status class I or II.
  • between 18 and 35 kg m-2.
  • No use of psychotropic or neuropsychiatric medications.
  • A airway assessment with no indication of a difficult intubation including a class I or II Mallampati airway and a mandible-to-hyoid distance of greater than three fingerbreadths.
  • Age between 18-75 years.

Exclusion criteria

Exclusion Criteria:

  • Does not meet inclusion criteria.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Sham comparator
    Group 1

    Saline 0.06 ml/kg

    Drug: Saline 0.06 ml/kg

  • Active comparator
    Group 2

    Rocuronium 0.2 mg/kg

    Drug: Rocuronium 0.2 mg/kg

  • Active comparator
    Group 3

    Rocuronium 0.4 mg/kg

    Drug: Rocuronium 0.4 mg/kg

  • Active comparator
    Group 4

    Rocuronium 0.6 mg/kg

    Drug: Rocuronium 0.6 mg/kg

Interventions

  • DrugSaline 0.06 ml/kg

    IV Infusion x1 prior to laryngoscopy

    Also known as: Normal Saline

  • DrugRocuronium 0.2 mg/kg

    Drug page: Rocuronium

    IV Infusion x1 prior to laryngoscopy

    Also known as: Rocuronium bromide: Zemuron

  • DrugRocuronium 0.4 mg/kg

    Drug page: Rocuronium

    IV Infusion x1 prior to laryngoscopy

    Also known as: Rocuronium bromide: Zemuron

  • DrugRocuronium 0.6 mg/kg

    Drug page: Rocuronium

    IV Infusion x1 prior to laryngoscopy

    Also known as: Rocuronium bromide: Zemuron

06

What researchers measure

Primary outcomes

  1. The Mean Difference in CVI Between Pre-laryngoscopy and Post-laryngoscopy for Each of the Four Rocuronium Groups

    The difference between the mean CVI in three minutes prior to laryngoscopy and three minutes following laryngoscopy reported as the mean change in CVI and the +/- 95% confidence interval for each group. The Composite Variability Index (CVI) scale is a logistic regression of three measures of processed electroencephalography (EEG) signals. These signals are Bispectral Index (BIS), the variability of electromyelogram (sEMG), and the variability of BIS (sBIS). The scale ranges from 0 to 100 where a lower CVI value represents a lower likelihood of intraoperative somatic responses, and a higher CVI value represents a higher likelihood of intraoperative somatic responses.

    Time frame: Six minutes after the dose of rocuronium with laryngoscopy at 3 minutes after the study intervention

Secondary outcomes

  1. The Average CVI During the Maintenance Phase of Anesthesia for the Two Remifentanil Groups

    Mean CVI from incision to propofol off reported as the mean CVI +/- 95% confidence interval for the two groups

    Time frame: Maintenance Anesthesia

07

Results

Posted May 12, 2017
Limitations and caveats
Sample size for this study calculation was based upon the assumption that that the expected mean of CVI would be 60 with a variance of 30 and that the variance of 30 would be equal for each group.

Participant flow

Participant flow — Overall Study
MilestoneGroup 1Group 2Group 3Group 4
Started20202020
Completed19192017
Not completed1103
Withdrew: Physician decision1103

Outcome measures

PrimaryThe Mean Difference in CVI Between Pre-laryngoscopy and Post-laryngoscopy for Each of the Four Rocuronium Groups

The difference between the mean CVI in three minutes prior to laryngoscopy and three minutes following laryngoscopy reported as the mean change in CVI and the +/- 95% confidence interval for each group. The Composite Variability Index (CVI) scale is a logistic regression of three measures of processed electroencephalography (EEG) signals. These signals are Bispectral Index (BIS), the variability of electromyelogram (sEMG), and the variability of BIS (sBIS). The scale ranges from 0 to 100 where a lower CVI value represents a lower likelihood of intraoperative somatic responses, and a higher CVI value represents a higher likelihood of intraoperative somatic responses.

Time frame:
Six minutes after the dose of rocuronium with laryngoscopy at 3 minutes after the study intervention
Reported as:
Mean · units on a scale
The Mean Difference in CVI Between Pre-laryngoscopy and Post-laryngoscopy for Each of the Four Rocuronium Groups
units on a scaleGroup 1Group 2Group 3Group 4
The Mean Difference in CVI Between Pre-laryngoscopy and Post-laryngoscopy for Each of the Four Rocuronium Groups2.40 (2.15 to 2.64)1.39 (0.95 to 1.83)0.48 (0.24 to 0.72)0.17 (-0.04 to 0.38)
Statistical analysis
  • Group 1 vs Group 2 vs Group 3 vs Group 4 · ANOVA · p = < 0.05 (Comparisons of the means were accomplished via student's t-test with Bonferroni correction for multiple comparisons.)
SecondaryThe Average CVI During the Maintenance Phase of Anesthesia for the Two Remifentanil Groups

Mean CVI from incision to propofol off reported as the mean CVI +/- 95% confidence interval for the two groups

Time frame:
Maintenance Anesthesia
Reported as:
Mean · units on a scale
The Average CVI During the Maintenance Phase of Anesthesia for the Two Remifentanil Groups
units on a scaleRemifentanil 2ng/mlRemifentanil 8 ng/ml
The Average CVI During the Maintenance Phase of Anesthesia for the Two Remifentanil Groups1.73 (1.56 to 1.9)1.38 (1.31 to 1.45)

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1—0/19 (0%)0/19 (0%)
Group 2—0/19 (0%)0/19 (0%)
Group 3—0/20 (0%)0/20 (0%)
Group 4—0/17 (0%)0/17 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group 1Group 2Group 3Group 4Total
Mean35.9 ± 12.338.6 ± 14.639.4 ± 12.732.9 ± 6.437.9 ± 11.34
Sex: Female, Male
Sex: Female, Male(Participants)Group 1Group 2Group 3Group 4Total
Female988934
Male101112841
08

Study locations

1 site
  • Fletcher Allen Health Care
    Burlington, Vermont 05405, United States
09

References and documents

Individual participant data

Plan to share: No — Data collected was for device algorithm development

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2017, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2011
First posted
Oct 12, 2011
Start
Jun 2009
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results first posted
May 12, 2017
Last update
May 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01450813
Lead sponsor
Medtronic - MITG
Responsible party
Sponsor
First posted
Oct 12, 2011
Start date
Jun 2009
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
May 12, 2017
Last update
May 12, 2017

Study contacts

Donald M Mathews, MD
principal investigator · University of Vermont

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rocuronium

Start the discussion